What the FDA labels say about taking them together
Ethinyl estradiol/segesterone and ritonavir
Ethinyl estradiol/segesterone's FDA label of April 23, 2025 names ritonavir in its contraindications section; the ritonavir label PlainMeds reads does not name ethinyl estradiol/segesterone. The ethinyl estradiol/segesterone label: “Significant decreases in systemic exposure of estrogen and/or progestin have been noted when CHCs are co-administered with some HIV protease inhibitors, some HCV protease inhibitors, and some non-nucleoside reverse …”
Check it at the source: the ethinyl estradiol/segesterone FDA label on DailyMed (effective April 23, 2025); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).
What does the ethinyl estradiol/segesterone label say about ritonavir?
Ethinyl estradiol/segesterone label, contraindicationsUse of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alanine transaminase (ALT) elevations [see Warnings and Precautions (5.3) ].
Ethinyl estradiol/segesterone label, drug interactionsSignificant decreases in systemic exposure of estrogen and/or progestin have been noted when CHCs are co-administered with some HIV protease inhibitors (eg, nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir), some HCV protease inhibitors (eg, boceprevir and telaprevir), and some non-nucleoside reverse transcriptase inhibitors (eg, nevirapine).
Ethinyl estradiol/segesterone label, warnings and precautionsElevations with Concomitant Hepatitis C Treatment During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with and without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in females using ethinyl estradiol-containing medications, such as ANNOVERA.
Source: FDA drug label (Annovera), Mayne Pharma, effective April 23, 2025 (SPL set eb18194f-2021-41fa-8bdf-31e0c0eb646b), via openFDA; the full label on DailyMed
What does the ritonavir label say about ethinyl estradiol/segesterone?
Ritonavir's label (effective July 23, 2026) does not name ethinyl estradiol/segesterone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ethinyl estradiol/segesterone | Ritonavir | |
|---|---|---|
| Labeled for | Birth control | HIV |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $2,315.29 per ring Annovera vaginal ring | $0.607 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once